๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

23 recruiting trials

for EGFR Mutant Advanced Non-small Cell Lung Cancer

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965NA1 site๐Ÿ“ Guangzhou Guangzhou University of Traditional Chinese Medicine ยท Tests: Furmonertinib 320mg qod po, Furmonertinib 160mg qd po Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites๐Ÿ“ Changchun๐Ÿ“ Chengdu๐Ÿ“ Dongguan Sun Yat-sen University ยท Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage โ…ข EGFR-mutant Non-small Cell Lung Cancer NCT07323056Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Sacituzumab Tirumotecan and Limertinib Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site๐Ÿ“ Busan Pusan National University Hospital ยท Tests: Local Therapy (Surgery or Radiotherapy) AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases NCT06604689n/a1 site๐Ÿ“ Shanghai Fudan University ยท Tests: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC NCT07742332Phase 21 site๐Ÿ“ Shanghai Peng Zhang ยท Tests: Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) NCT07680790Phase 3204 sites๐Ÿ“ Beverly Hills๐Ÿ“ Fullerton๐Ÿ“ La Jolla Bristol-Myers Squibb ยท Tests: Iza-bren, Osimertinib, Pemetrexed, Carboplatin, Cisplatin A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases NCT07143045n/a34 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Alpha Biopharma (Jiangsu) Co., Ltd. ยท Tests: zorifertinib MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer NCT04762199Phase 11 site๐Ÿ“ Atlanta Emory University ยท Tests: Flt3/MerTK Inhibitor MRX-2843, Osimertinib Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) NCT05642572Phase 2454 sites๐Ÿ“ Daphne๐Ÿ“ Fairhope๐Ÿ“ Mobile SWOG Cancer Research Network ยท Tests: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW NCT06355609Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: sunvozertinib in combination with Anlotinib Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC NCT04324164n/a1 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: Third-generation EGFR-TKI, EGFR-TKI EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC NCT07637448Phase 21 site๐Ÿ“ Guangzhou Nanfang Hospital, Southern Medical University ยท Tests: EGFR-TKIs Combined with PD-1 Monoclonal Antibody Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial NCT06363734Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Osimertinib plus Dalpiciclib High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI NCT06652048Phase 21 site๐Ÿ“ Shanghai Jialei Wang ยท Tests: Furmonertinib 160mg QD, Furmonertinib 240mg QD, Furmonertinib 160mg QD plus Chemotherapy A Phase โ… /โ…กa Clinical Study of GEN-725 in Combination With Dositinib NCT07362940Phase 1, Phase 25 sites๐Ÿ“ Beijing๐Ÿ“ Changsha๐Ÿ“ Jinan Henan Genuine Biotech Co., Ltd. ยท Tests: GEN-725 tablets + Dositinib mesylate tablets Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer NCT04181060Phase 3603 sites๐Ÿ“ Anchorage๐Ÿ“ Anchorage๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study NCT07518160Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Shanghai Shanghai Junshi Bioscience Co., Ltd. ยท Tests: JS212 for Injection๏ผ‹JS111 capsules (AP-L1898) Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib NCT04486833Phase 1, Phase 210 sites๐Ÿ“ Los Angeles๐Ÿ“ Lone Tree๐Ÿ“ Urbana Genprex, Inc. ยท Tests: quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC NCT05394831Phase 1, Phase 210 sites๐Ÿ“ Orange๐Ÿ“ Goyang-si๐Ÿ“ Cheongju-si J Ints Bio ยท Tests: JIN-A02 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189Phase 145 sites๐Ÿ“ Lexington๐Ÿ“ Louisville๐Ÿ“ Baltimore BioNTech SE ยท Tests: BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer NCT07028489n/a10 sites๐Ÿ“ Monterey๐Ÿ“ Torrance๐Ÿ“ Walnut Creek N-Power Medicine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy